

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.

10271-131-999

APPLICATION NO.

10/565,771

APPLICANT

Michael S. Kinch

FILING DATE

January 23, 2006

ART UNIT

To Be Assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A01	5,416,192	05/16/95	Shoyab et al.	
	A02	4,474,893	10/02/84	Reading	
	A03	4,714,681	12/22/87	Reading	
	A04	4,925,648	05/15/90	Hansen et al.	
	A05	5,573,920	11/12/96	Randle	
	A06	5,601,819	02/11/97	Wong et al.	
	A07	6,309,826	10/30/01	Serrero	
	A08	6,670,183	12/30/03	Serrero	
	A09	6,720,159	04/13/04	Serrero	
	A10	2003/0108950	06/12/03	Serrero	
	A11	2005/0175616	08/11/05	Kiener et al.	

FOREIGN PATENT DOCUMENTS

		FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	T
	B01	WO 91/003060	03/07/91	The Furukawa Electric Co., Ltd	English only abstract.	
	B02	WO 92/04793	03/19/92	Minnesota Mining and Manufacturing Company		
	B03	WO 92/08802	5/29/92	Cetus Corporation		
	B04	WO 93/17715	9/16/93	Board of Regents, University of Texas System		
	B05	WO 98/52607	11/26/98	Serrero, G.		
	B06	WO 05/000207	01/06/05	MedImmune, Inc.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C01	BATEMAN et al., 1990, "Granulins, a novel class of peptide from leukocytes" Biochem. Biophys. Res. Commun. 173(3):1161-8	
	C02	BOSTWICK, 1996, "Progression of prostatic intraepithelial neoplasia to early invasive adenocarcinoma" Eur Urol. 30(2): 145-52	
	C03	BRANCH et al., 2000, "A good antisense Molecule is Hard to Find." Trends Biochem Sci.. 23:45-50	

EXAMINER
NYJD-1609831v2**DATE CONSIDERED**

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. AH/

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)ATTY. DOCKET NO.
10271-131-999APPLICATION NO.
10/565,771APPLICANT
Michael S. KinchFILING DATE
January 23, 2006ART UNIT
To Be Assigned**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C04	BRAWER, 1999, "Prostate-specific antigen: current status." CA A Cancer Journal for Clinicians 49(5): 264-81	
	C05	CARLES-KINCH et al., 2002, "Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior." Cancer Res. 62: 2840-7	
	C06	CHENG et al., 1996, "Expression of E-cadherin in primary and metastatic prostate cancer" Am. J. Pathol. 148(5): 1375-80	
	C07	CROOKE et al., 1998, "Basic Principles of Antisense Therapeutics." Chapter 1:1-50	
	C08	GENBANK ACCESSION NO. NM_002087, "Homo sapiens granulin (GRN), transcript variant 1, mRNA" 04/16/06	
	C09	GENBANK ACCESSION NO. AY124489, "Homo sapiens PC cell-derived growth factor (GRN) mRNA, complete cds" 08/14/2002	
	C10	GENBANK ACCESSION NO. BC049368, "Homo sapiens TYRO3 protein tyrosine kinase, mRNA (cDNA clone MGC:57186 IMAGE:4821587), complete cds" 07/30/2005	
	C11	GENBANK ACCESSION NO. BC051756, "Homo sapiens TYRO3 protein tyrosine kinase, mRNA (cDNA clone MGC:51900 IMAGE:6095596), complete cds" 06/30/2004	
	C12	GENBANK ACCESSION NO. M75161, "H.sapiens granulin mRNA, complete cds" 12/31/1994	
	C13	GENBANK ACCESSION NO. NM_006293, "Homo sapiens TYRO3 protein tyrosine kinase (TYRO3), mRNA" 01/08/2006	
	C14	GREEN et al., 2000, "Antisense Oligonucleotides: An Evolving Technology for the Modulation of Gene Expression in Human Diseases" Vol. 91:93-105	
	C15	JEN et al., 2000, "Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies." Stem Cells. 8:307-319	
	C16	JIANG et al., 2002, "Expression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma" Am. J. Pathol. 160: 667-71	
	C17	KOSTELNY et al., 1992, "Formation of a bispecific antibody by the use of leucine zippers" J. Immunol. 148(5):1547-1553	
	C18	OESTERLING, 1991, "Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate." J. of Urol., 145(5): 907-23	
	C19	PAN et al., 2004, "PC cell-derived growth factor expression in prostatic intraepithelial neoplasia and prostatic adenocarcinoma." Clin. Canc. Res. 10:1333-1337	
	C20	PLOWMAN et al., 1992, "The epithelin precursor encodes two proteins with opposing activities on epithelial cell growth" J. Biol. Chem. 267(18): 13073-8	
	C21	TUTT et al., 1991, "Trispecific F(ab')3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells." J. Immunol. 147(1):60-69	
	C22	ZANTEK et al., 1999, "E-cadherin regulates the function of the EphA2 receptor tyrosine kinase" Cell Growth Diff. 10(9): 629-38	
	C23	ZHOU et al., 1993, "Purification of an autocrine growth factor homologous with mouse epithelin precursor from a highly tumorigenic cell line" J. Biol. Chem. 268(15): 10863-9	

EXAMINER /Alana M. Harris/
NYJD-1609831v2

DATE CONSIDERED September 3, 2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. AH/